Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
AIDS Res Hum Retroviruses ; 37(2): 109-121, 2021 02.
Article in English | MEDLINE | ID: mdl-33045840

ABSTRACT

Despite the considerable progress that has been made in identifying cellular factors and pathways that contribute to establishment and maintenance of the latent HIV reservoir, it remains the major obstacle to eradicating this virus. Most recently, noncoding genes have been implicated in regulation of HIV expression. In this study, small RNA sequencing was used to profile expression of microRNAs (miRNAs) in a primary CD4+ T cell in vitro model of HIV latency. Previously, we have shown that protein-coding genes dysregulated in this model were enriched for the p53 signaling pathway, which was confirmed experimentally. We further found a link between p53 signaling and dysregulated long noncoding RNAs. In this study, we hypothesized that miRNAs may provide an additional level of regulation of the p53 signaling pathway during HIV latency. Twenty-six miRNAs were identified to be dysregulated in our latency model. A subset of these miRNAs was validated by real-time quantitative polymerase chain reaction. Predicted messenger RNA (mRNA) targets and cellular pathways enriched for mRNA targets were identified using several analytical methods. Our analyses showed that many protein-coding genes and pathways targeted by dysregulated miRNAs have relevance to regulation of HIV expression or establishment of HIV latency. The p53 signaling pathway was found among pathways that were targeted by dysregulated miRNAs at a greater level than expected by chance. This study provides a mechanistic insight into regulation of the p53 pathway through miRNAs that may contribute to the establishment of latency.


Subject(s)
HIV Infections , HIV-1 , MicroRNAs , RNA, Long Noncoding , Gene Expression Profiling , HIV-1/genetics , Humans , MicroRNAs/genetics , Virus Latency
2.
Int J Mol Sci ; 18(2)2017 Feb 01.
Article in English | MEDLINE | ID: mdl-28157153

ABSTRACT

Reverse vaccinology (RV) is a bioinformatics approach that can predict antigens with protective potential from the protein coding genomes of bacterial pathogens for subunit vaccine design. RV has become firmly established following the development of the BEXSERO® vaccine against Neisseria meningitidis serogroup B. RV studies have begun to incorporate machine learning (ML) techniques to distinguish bacterial protective antigens (BPAs) from non-BPAs. This research contributes significantly to the RV field by using permutation analysis to demonstrate that a signal for protective antigens can be curated from published data. Furthermore, the effects of the following on an ML approach to RV were also assessed: nested cross-validation, balancing selection of non-BPAs for subcellular localization, increasing the training data, and incorporating greater numbers of protein annotation tools for feature generation. These enhancements yielded a support vector machine (SVM) classifier that could discriminate BPAs (n = 200) from non-BPAs (n = 200) with an area under the curve (AUC) of 0.787. In addition, hierarchical clustering of BPAs revealed that intracellular BPAs clustered separately from extracellular BPAs. However, no immediate benefit was derived when training SVM classifiers on data sets exclusively containing intra- or extracellular BPAs. In conclusion, this work demonstrates that ML classifiers have great utility in RV approaches and will lead to new subunit vaccines in the future.


Subject(s)
Antigens, Bacterial/immunology , Bacterial Vaccines/immunology , Computational Biology/methods , Machine Learning , Vaccines, Subunit/immunology , Antigens, Bacterial/genetics , Area Under Curve , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Bacterial Vaccines/genetics , Epitope Mapping , Epitopes/genetics , Epitopes/immunology , Humans , Mutagenesis , ROC Curve , Support Vector Machine , Vaccines, Subunit/genetics
3.
PLoS Pathog ; 12(11): e1006026, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27898737

ABSTRACT

The search for an HIV-1 cure has been greatly hindered by the presence of a viral reservoir that persists despite antiretroviral therapy (ART). Studies of HIV-1 latency in vivo are also complicated by the low proportion of latently infected cells in HIV-1 infected individuals. A number of models of HIV-1 latency have been developed to examine the signaling pathways and viral determinants of latency and reactivation. A primary cell model of HIV-1 latency, which incorporates the generation of primary central memory CD4 T cells (TCM), full-length virus infection (HIVNL4-3) and ART to suppress virus replication, was used to investigate the establishment of HIV latency using RNA-Seq. Initially, an investigation of host and viral gene expression in the resting and activated states of this model indicated that the resting condition was reflective of a latent state. Then, a comparison of the host transcriptome between the uninfected and latently infected conditions of this model identified 826 differentially expressed genes, many of which were related to p53 signaling. Inhibition of the transcriptional activity of p53 by pifithrin-α during HIV-1 infection reduced the ability of HIV-1 to be reactivated from its latent state by an unknown mechanism. In conclusion, this model may be used to screen latency reversing agents utilized in shock and kill approaches to cure HIV, to search for cellular markers of latency, and to understand the mechanisms by which HIV-1 establishes latency.


Subject(s)
CD4-Positive T-Lymphocytes/virology , Gene Expression Profiling/methods , HIV Infections/virology , HIV-1/physiology , Signal Transduction/physiology , Tumor Suppressor Protein p53/metabolism , Virus Latency/physiology , Flow Cytometry , Humans , Immunologic Memory , In Vitro Techniques , Polymerase Chain Reaction , Transcriptome
4.
Antiviral Res ; 123: 78-85, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26343910

ABSTRACT

Suberoylanilide hydroxamic acid (SAHA) has been assessed in clinical trials as part of a "shock and kill" strategy to cure HIV-infected patients. While it was effective at inducing expression of HIV RNA ("shock"), treatment with SAHA did not result in a reduction of reservoir size ("kill"). We therefore utilized a combined analysis of effects of SAHA on the host transcriptome and proteome to dissect its mechanisms of action that may explain its limited success in "shock and kill" strategies. CD4+ T cells from HIV seronegative donors were treated with 1µM SAHA or its solvent dimethyl sulfoxide (DMSO) for 24h. Protein expression and post-translational modifications were measured with iTRAQ proteomics using ultra high-precision two-dimensional liquid chromatography-tandem mass spectrometry. Gene expression was assessed by Illumina microarrays. Using limma package in the R computing environment, we identified 185 proteins, 18 phosphorylated forms, 4 acetylated forms and 2982 genes, whose expression was modulated by SAHA. A protein interaction network integrating these 4 data types identified the HIV transcriptional repressor HMGA1 to be upregulated by SAHA at the transcript, protein and acetylated protein levels. Further functional category assessment of proteins and genes modulated by SAHA identified gene ontology terms related to NFκB signaling, protein folding and autophagy, which are all relevant to HIV reactivation. In summary, SAHA modulated numerous host cell transcripts, proteins and post-translational modifications of proteins, which would be expected to have very mixed effects on the induction of HIV-specific transcription and protein function. Proteome profiling highlighted a number of potential counter-regulatory effects of SAHA with respect to viral induction, which transcriptome profiling alone would not have identified. These observations could lead to a more informed selection and design of other HDACi with a more refined targeting profile, and prioritization of latency reversing agents of other classes to be used in combination with SAHA to achieve more potent induction of HIV expression.


Subject(s)
Gene Expression Profiling , HIV/physiology , Hydroxamic Acids/metabolism , Proteome/analysis , Virus Activation/drug effects , Virus Latency/drug effects , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/virology , Cells, Cultured , Chromatography, Liquid , Humans , Microarray Analysis , Tandem Mass Spectrometry , Vorinostat
5.
Viruses ; 3(2): 160-171, 2011 Feb.
Article in English | MEDLINE | ID: mdl-22049308

ABSTRACT

Flaviviruses, such as dengue virus and West Nile virus, are enveloped viruses that infect cells through receptor-mediated endocytosis and fusion from within acidic endosomes. The cell entry process of flaviviruses is mediated by the viral E glycoprotein. This short review will address recent advances in the understanding of flavivirus cell entry with specific emphasis on the recent study of Zaitseva and coworkers, indicating that anionic lipids might play a crucial role in the fusion process of dengue virus [1].


Subject(s)
Dengue Virus/metabolism , Membrane Lipids/metabolism , Virus Internalization , West Nile virus/metabolism , Cell Membrane/metabolism , Cell Membrane/virology , Dengue/metabolism , Dengue/virology , Endocytosis , Endosomes/chemistry , Endosomes/metabolism , Endosomes/virology , Humans , Membrane Fusion , Viral Envelope Proteins/metabolism , West Nile Fever/metabolism , West Nile Fever/virology
6.
J Virol ; 85(22): 11800-8, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21880758

ABSTRACT

Flavivirus-infected cells secrete a mixture of mature, partially immature, and fully immature particles into the extracellular space. Although mature virions are highly infectious, prM-containing fully immature virions are noninfectious largely because the prM protein inhibits the cell attachment and fusogenic properties of the virus. If, however, cell attachment and entry are facilitated by anti-prM antibodies, immature flavivirus becomes infectious after efficient processing of the prM protein by the endosomal protease furin. A recent study demonstrated that E53, a cross-reactive monoclonal antibody (MAb) that engages the highly conserved fusion-loop peptide within the flavivirus envelope glycoprotein, preferentially binds to immature flavivirus particles. We investigated here the infectious potential of fully immature West Nile virus (WNV) and dengue virus (DENV) particles opsonized with E53 MAb and observed that, like anti-prM antibodies, this anti-E antibody also has the capacity to render fully immature flaviviruses infectious. E53-mediated enhancement of both immature WNV and DENV depended on efficient cell entry and the enzymatic activity of the endosomal furin. Furthermore, we also observed that E53-opsonized immature DENV particles but not WNV particles required a more acidic pH for efficient cleavage of prM by furin, adding greater complexity to the dynamics of antibody-mediated infection of immature flavivirus virions.


Subject(s)
Antibodies, Viral/metabolism , Antibody-Dependent Enhancement , Viral Envelope Proteins/immunology , Viral Envelope Proteins/metabolism , Animals , Antibodies, Monoclonal , Cell Line , Cricetinae , Dengue Virus/immunology , Dengue Virus/pathogenicity , Furin/metabolism , Hydrogen-Ion Concentration , Virus Internalization , West Nile virus/immunology , West Nile virus/pathogenicity
7.
J Gen Virol ; 92(Pt 10): 2281-2285, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21697345

ABSTRACT

West Nile virus (WNV) is a member of the family Flaviviridae and is a neurotropic pathogen responsible for severe human disease. Flavivirus-infected cells release virus particles that contain variable numbers of precursor membrane (prM) protein molecules at the viral surface. Consequently, antibodies are produced against the prM protein. These antibodies have been shown to activate the infectious potential of fully immature flavivirus particles in vitro. Here, we provide in vivo proof that prM antibodies render immature WNV infectious. Infection with antibody-opsonized immature WNV particles caused disease and death of mice, and infectious WNV was found in the brains and sera.


Subject(s)
Antibodies, Blocking/metabolism , Antibodies, Viral/metabolism , Antibody-Dependent Enhancement , Viral Envelope Proteins/immunology , Viral Envelope Proteins/metabolism , Virus Internalization , Animals , Brain/virology , Disease Models, Animal , Mice , Rodent Diseases/mortality , Rodent Diseases/pathology , Rodent Diseases/virology , Serum/virology , West Nile Fever/mortality , West Nile Fever/pathology , West Nile Fever/virology
8.
J Gen Virol ; 91(Pt 2): 389-93, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19828760

ABSTRACT

Flaviviruses infect their host cells by a membrane fusion reaction. In this study, we performed a functional analysis of the membrane fusion properties of West Nile virus (WNV) with liposomal target membranes. Membrane fusion was monitored continuously using a lipid mixing assay involving the fluorophore, pyrene. Fusion of WNV with liposomes occurred on the timescale of seconds and was strictly dependent on mildly acidic pH. Optimal fusion kinetics were observed at pH 6.3, the threshold for fusion being pH 6.9. Preincubation of the virus alone at pH 6.3 resulted in a rapid loss of fusion capacity. WNV fusion activity is strongly promoted by the presence of cholesterol in the target membrane. Furthermore, we provide direct evidence that cleavage of prM to M is a requirement for fusion activity of WNV.


Subject(s)
Membrane Fusion , West Nile Fever/physiopathology , West Nile virus/physiology , Animals , Cricetinae , Humans , Hydrogen-Ion Concentration , Liposomes/chemistry , West Nile Fever/virology , West Nile virus/chemistry
9.
PLoS Pathog ; 5(5): e1000453, 2009 May.
Article in English | MEDLINE | ID: mdl-19478866

ABSTRACT

Defining the precise cellular mechanisms of neutralization by potently inhibitory antibodies is important for understanding how the immune system successfully limits viral infections. We recently described a potently inhibitory monoclonal antibody (MAb E16) against the envelope (E) protein of West Nile virus (WNV) that neutralizes infection even after virus has spread to the central nervous system. Herein, we define its mechanism of inhibition. E16 blocks infection primarily at a post-attachment step as antibody-opsonized WNV enters permissive cells but cannot escape from endocytic compartments. These cellular experiments suggest that E16 blocks the acid-catalyzed fusion step that is required for nucleocapsid entry into the cytoplasm. Indeed, E16 directly inhibits fusion of WNV with liposomes. Additionally, low-pH exposure of E16-WNV complexes in the absence of target membranes did not fully inactivate infectious virus, further suggesting that E16 prevents a structural transition required for fusion. Thus, a strongly neutralizing anti-WNV MAb with therapeutic potential is potently inhibitory because it blocks viral fusion and thereby promotes clearance by delivering virus to the lysosome for destruction.


Subject(s)
Antibodies, Viral/pharmacology , West Nile Fever/immunology , West Nile virus/immunology , Antibodies, Monoclonal , Antibodies, Viral/therapeutic use , Endosomes/virology , Lysosomes/virology , Viral Envelope Proteins/immunology , Virus Internalization
10.
J Virol ; 83(13): 6494-507, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19386704

ABSTRACT

West Nile virus (WNV) is a neurotropic flavivirus that is now a primary cause of epidemic encephalitis in North America. Studies of mice have demonstrated that the humoral immune response against WNV limits primary infection and protects against a secondary challenge. The most-potent neutralizing mouse monoclonal antibodies (MAbs) recognize an epitope on the lateral ridge of domain III (DIII-lr) of the envelope (E) protein. However, studies with serum from human patients show that antibodies against the DIII-lr epitope comprise, at best, a minor component of the human anti-WNV antibody response. Herein, we characterize in detail two WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B-cell populations of convalescent patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection in vivo, and yet poorly recognize recombinant forms of the E protein. Instead, CR4348 and CR4354 bind determinants on intact WNV virions and subviral particles in a pH-sensitive manner, and neutralization is altered by mutations at the dimer interface in domain II and the hinge between domains I and II, respectively. CR4348 and CR4354 human MAbs neutralize infection at a postattachment step in the viral life cycle, likely by inhibiting acid-induced fusion within the endosome.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Viral/immunology , West Nile Fever/prevention & control , West Nile virus/immunology , Animals , Antibody Specificity/immunology , B-Lymphocytes/immunology , Cell Line , Epitope Mapping , Humans , Mice , Mice, Inbred C57BL , Neutralization Tests , Protein Structure, Tertiary , Recombinant Proteins/immunology , Substrate Specificity , Viral Envelope Proteins/immunology , West Nile Fever/immunology , West Nile virus/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...